-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IRnaecZE7wTf9LZscNzFCt8V64Squov31j1GY4Vq/Xhv8mNxhjbMfjdf2MMEK/B6
 Fs3cjy5Pl0EZAKSvMNkQ/w==

<SEC-DOCUMENT>/in/edgar/work/20000703/0000912057-00-030726/0000912057-00-030726.txt : 20000920
<SEC-HEADER>0000912057-00-030726.hdr.sgml : 20000920
ACCESSION NUMBER:		0000912057-00-030726
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20000703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENOME THERAPEUTICS CORP
		CENTRAL INDEX KEY:			0000356830
		STANDARD INDUSTRIAL CLASSIFICATION:	 [2835
]		IRS NUMBER:				042297484
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0831
</COMPANY-DATA>

		FILING VALUES:
			FORM TYPE:		424B5
			SEC ACT:		
			SEC FILE NUMBER:	333-32614
			FILM NUMBER:		667001
</FILING-VALUES>

			BUSINESS ADDRESS:	
				STREET 1:		1OO BEAVER ST
				CITY:			WALTHAM
				STATE:			MA
				ZIP:			02453
				BUSINESS PHONE:		7813982300
</BUSINESS-ADDRESS>

				MAIL ADDRESS:	
					STREET 1:		100 BEAVER STREET
					CITY:			WALTHAM
					STATE:			MA
					ZIP:			02453
</MAIL-ADDRESS>

					FORMER COMPANY:	
						FORMER CONFORMED NAME:	COLLABORATIVE RESEARCH INC
						DATE OF NAME CHANGE:	19920703
</FORMER-COMPANY>
</FILER>
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a424b5.txt
<DESCRIPTION>424B5
<TEXT>

<PAGE>
                        FILED PURSUANT TO RULE 424(B)(5)
                               FILE NO. 333-32614
                  PRICING SUPPLEMENT NO. 3 DATED JUNE 30, 2000
                      (TO PROSPECTUS DATED JUNE 21, 2000).
                                 227,000 SHARES
                           GENOME THERAPEUTICS CORP.
                                  COMMON STOCK

                            ------------------------

    On June 30, 2000, we sold 227,000 shares of our common stock, par value
$0.10 per share (the "Common Stock"), at a weighted average price of $30.4356
per share through our agent, Tucker Anthony Incorporated, in transactions
effected through the Nasdaq National Market.

<TABLE>
<S>                                                           <C>
Gross Proceeds to Genome Therapeutics Corp..................  $6,908,881.20

Commission to Tucker Anthony................................  $  138,243.00

Net Proceeds to Genome Therapeutics Corp....................  $6,770,638.20

On June 30, 2000 the last reported sales price of the Common
  Stock on the
  Nasdaq National Market was................................  $       30.50
</TABLE>

                            ------------------------

Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----